Clinical Trial Update: Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating chidamide for refractory or relapsed peripheral T cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: UNKNOWN